Fluorescence in‐situ hybridisation for TP63 rearrangements in T cell lymphomas: single‐site experience of 470 patients and implications for clinical testing

The aims of this study were to review our 5‐year experience with clinical FISH testing for TP63 rearrangements using both TP63 break‐apart (BAP) and TBL1XR1/TP63 dual‐fusion (D‐FISH) probes to evaluate the frequency of TP63 rearrangements and the distribution of TBL1XR1 vs. alternate partner loci, and to assess whether both probe sets are necessary in all cases undergoing FISH testing.

[1]  Joshua M. Dempster,et al.  Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models , 2018, Nature Communications.

[2]  Z. Xiao,et al.  A double dealing tale of p63: an oncogene or a tumor suppressor , 2017, Cellular and Molecular Life Sciences.

[3]  M. Lim,et al.  Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  O. Abdel-Wahab,et al.  Diagnosis and classification of hematologic malignancies on the basis of genetics. , 2017, Blood.

[5]  A. Feldman,et al.  DUSP22 AND TP63 REARRANGEMENTS PREDICT OUTCOME OF ALK‐NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: A DANISH COHORT STUDY , 2017, Blood.

[6]  A. Feldman,et al.  Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. , 2017, Human pathology.

[7]  G. Inghirami,et al.  The heterogeneous landscape of ALK negative ALCL , 2017, Oncotarget.

[8]  Sarah H. Johnson,et al.  Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma , 2015, Modern Pathology.

[9]  A. Feldman,et al.  Anaplastic Large Cell Lymphomas: ALK Positive, ALK Negative, and Primary Cutaneous , 2015, Advances in anatomic pathology.

[10]  A. Feldman,et al.  Somatic rearrangement of the TP63 gene preceding development of mycosis fungoides with aggressive clinical course , 2014, Blood Cancer Journal.

[11]  W. Wilson,et al.  ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. , 2014, Blood.

[12]  David I. Smith,et al.  Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. , 2012, Blood.

[13]  Ryan D. Morin,et al.  TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. , 2012, Blood.

[14]  David I. Smith,et al.  Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. , 2011, Blood.